A Phase 3 interventional study of Placebo and Denosumab in Breast Cancer, sponsored by Amgen. Completed at 47 sites in 2 countries. Open to female participants aged 45 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-07-27.
Sponsored by Amgen · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing denosumab in Breast Neoplasms — none open to participants now, 3 under way, 2 of them phase 3. Denosumab · Breast Neoplasms.
Among the 24 studies testing denosumab in Breast Neoplasms, this one is the 2nd largest by enrollment, is one of 2 that started in 2006, is one of 9 in phase 3, and was the 4th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →None of the 24 studies testing denosumab in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 45 Years to 100 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,420 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 53 across the 24 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 24 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
30 studies in Breast Neoplasms by Amgen: none open now, 1 under way, 1 of them phase 3. Of 29 finished, 16 (55%) have results posted.
Among the 30 studies in Breast Neoplasms by Amgen, this one is the 2nd largest by enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2006, is one of 10 in phase 3, and was the 16th registered.
Amgen’s Breast Neoplasms studies by the year they started, since 2002.
1 of the studies testing denosumab in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04711109Phase 3Alliance for Clinical Trials in OncologyStudying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies testing denosumab in Breast Neoplasms, from their registry updates:
Among Amgen’s 30 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether denosumab compared to placebo, will reduce the rate of first clinical fracture in women with non-metastatic breast cancer receiving (non-steroidal) aromatase inhibitor therapy.
Participants will remain on treatment until the required number of events (where an event is defined as first clinical fracture) is reached and all participants have had the opportunity to receive a minimum of at least 2 doses of study drug, whichever occurs later. The primary analysis data cut-off date (PADCD) is defined as the time at which the required number of events is reached and all participants have had the opportunity to receive at least 2 doses of study drug. When the PADCD is reached, all participants will discontinue study drug.
Following the study PADCD, participants will be followed every 12 months starting from their last study visit until a maximum of 66 months after PADCD.
After approval of Amendment 4, willing and eligible participants randomized to placebo during the double-blind phase may participate in an open-label phase (OLP) and receive denosumab 60 mg Q6M for up to 36 months (maximum of 7 doses).
After approval of Amendment 6 in 2019 a zoledronic acid (ZA) substudy was added to the protocol. Willing and eligible participants who participated in the OLP of the study and completed open-label denosumab may opt in to this ZA substudy and either receive a single dose of ZA (Therapy Arm), or be managed according to the current standard of care for this patient population (Control Arm).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
woman, defined as a woman fulfilling any one of the following criteria:
Exclusion Criteria for Double Blinded Phase:
Inclusion Criteria to Receive Open-label Phase Denosumab:
Exclusion Criteria to Receive Open-label Phase Denosumab:
Subjects meeting the following criteria for oral bisphosphonate treatment:
Eligibility for ZA substudy Inclusion Criteria
Known history of any of the following conditions either by subject self report or chart review
Known liver or renal disease as determined by the investigator and indicated by the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 60 mg denosumab subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.
Biological: Denosumab · Drug: Non-steroidal aromatase inhibitor therapy
Participants received placebo subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.
Drug: Placebo · Drug: Non-steroidal aromatase inhibitor therapy
Eligible participants who completed the open-label phase could be enrolled into the zoledronic acid substudy and randomized to receive a single 5 mg intravenous dose of zoledronic acid 8 months after the last open-label dose of denosumab.
Drug: Zoledronic Acid
Eligible participants who completed the open-label phase could be enrolled into the zoledronic acid substudy and randomized to receive standard of care 8 months after the last open-label dose of denosumab.
Other: Standard of Care
Also known as: Administered as a subcutaneous injection
Administered as a subcutaneous injection
Also known as: Prolia®
An approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting
5 mg zoledronic acid administered at a constant infusion rate
Also known as: Reclast, Zometa
Standard of care (SoC) as recommended by the treating physician, depending on individual factors such as bone density, lifestyle recommendations by the Investigator such as diet, physical activities and sun exposure, as well as local treatment standards.
This study also gives Anastrozole. No intervention listed here names it: that was found by reading the record.
Time to First Clinical Fracture
The time to first on-study clinical fracture was defined as the number of days from randomization to the date of the x-ray confirming the clinical fracture. A clinical fracture is any clinically evident fracture with associated symptoms and confirmed by x-ray. Participants who died or withdrew without experiencing a clinical fracture were censored at the date of last contact or study termination whichever was earlier.
Time frame: From randomization until the primary analysis cut-off date of 26 March 2014; maximum time on main study at the cut-off was 87 months
Percent Change From Baseline in Total Lumbar Spine Bone Mineral Density (BMD) at Month 36 at Pre-selected Sites
Bone mineral density was assessed by dual x-ray absorptiometry.
Time frame: Baseline and Month 36
Percent Change From Baseline in Total Hip BMD at Month 36 at Pre-selected Sites
Bone mineral density was assessed by dual x-ray absorptiometry.
Time frame: Baseline and Month 36
Percent Change From Baseline in Femoral Neck BMD at Month 36 at Pre-selected Sites
Bone mineral density was assessed by dual x-ray absorptiometry.
Time frame: Baseline and Month 36
Number of Participants With New Vertebral Fractures
Assessment of vertebral fractures was performed by an expert radiologist at the central imaging center using a semiquantitative grading scale: Grade 1, 20% to 25% reduction in vertebral height (anterior, middle, or posterior); Grade 2, 25% to 40% reduction in height; Grade 3, greater than 40% reduction in height. A new vertebral fracture was defined as a fracture in a previously undeformed vertebrae including new compression fractures, defined as those compression fractures having a decrease in total anterior or posterior height of at least 25% from baseline. New vertebral fractures includes morphometric vertebral fractures identified from on study x-rays and clinical vertebral fractures confirmed by x-rays.
Time frame: 36 months
Number of Participants With New or Worsening Vertebral Fractures
Assessment of vertebral fractures was performed by an expert radiologist at the central imaging center using a semiquantitative grading scale: Grade 1, 20% to 25% reduction in vertebral height (anterior, middle, or posterior); Grade 2, 25% to 40% reduction in height; Grade 3, greater than 40% reduction in height. A new vertebral fracture was defined as a fracture in a previously undeformed vertebrae including new compression fractures, defined as those compression fractures having a decrease in total anterior or posterior height of at least 25% from baseline. New vertebral fractures includes morphometric vertebral fractures identified from on study x-rays and clinical vertebral fractures confirmed by x-rays. Worsening of pre-existing fractures was defined as an increase in fracture severity of at least 1 grade on the semiquantitative scale.
Time frame: 36 months
Disease-free Survival (DFS)
DFS was defined as the time interval from the randomization date to the date of first evidence of local or distant metastases, contra-lateral breast cancer, secondary carcinoma, or death from any cause (whichever occurred first). Participants last known to be alive, who did not experience recurrence of disease, were censored at their last contact date or at the data cut-off date whichever came first.
Time frame: From randomization until the DFS data cut-off date of 15 September 2015; maximum time on main study at the cut-off was 102 months
Bone Metastases-free Survival (BMFS)
BMFS was defined as the time interval from randomization to first occurrence of bone metastasis or death from any cause, whichever comes first. Participants last known to be alive, who did not experience bone metastasis, were censored at their last assessment (i.e., bone scan) date or at the last contact date, whichever comes first.
Time frame: From randomization until end of main study, maximum time on main study was 152 months
Overall Survival (OS)
OS was defined as the time from randomization to death from any cause.
Time frame: Randomization until end of main study, maximum duration of main study was 152 months
Participants were enrolled at 58 centers in Austria and Sweden from December 2006 to August 2020. Data collected during the exploratory ZA substudy were not used for the final analysis of the main study.
| Milestone | Placebo | Denosumab |
|---|---|---|
| Started | 1709 | 1711 |
| Received study drug in the double-blind phase | 1699 | 1700 |
| Continued into the open-label phase | 268 | 3 |
| Safety analysis set | 1690 | 1709 |
| Completed | 1242 | 1362 |
| Not completed | 467 | 349 |
| Withdrew: Withdrawal by subject | 235 | 205 |
| Withdrew: Death | 158 | 127 |
| Withdrew: Lost to follow-up | 24 | 17 |
| Withdrew: Continuing into zoledronic acid substudy | 50 | 0 |
The time to first on-study clinical fracture was defined as the number of days from randomization to the date of the x-ray confirming the clinical fracture. A clinical fracture is any clinically evident fracture with associated symptoms and confirmed by x-ray. Participants who died or withdrew without experiencing a clinical fracture were censored at the date of last contact or study termination whichever was earlier.
| Days | Placebo | Denosumab |
|---|---|---|
| Time to First Clinical Fracture | NA (NA to NA) | NA (NA to NA) |
Bone mineral density was assessed by dual x-ray absorptiometry.
| Percent Change in BMD | Placebo | Denosumab |
|---|---|---|
| Percent Change From Baseline in Total Lumbar Spine Bone Mineral Density (BMD) at Month 36 at Pre-selected Sites | -2.75 (-3.44 to -2.07) | 7.27 (6.56 to 7.98) |
Bone mineral density was assessed by dual x-ray absorptiometry.
| Percent Change in BMD | Placebo | Denosumab |
|---|---|---|
| Percent Change From Baseline in Total Hip BMD at Month 36 at Pre-selected Sites | -3.32 (-4.06 to -2.58) | 4.60 (3.85 to 5.35) |
Bone mineral density was assessed by dual x-ray absorptiometry.
| Percent Change in BMD | Placebo | Denosumab |
|---|---|---|
| Percent Change From Baseline in Femoral Neck BMD at Month 36 at Pre-selected Sites | -3.10 (-3.72 to -2.48) | 3.41 (2.78 to 4.04) |
Assessment of vertebral fractures was performed by an expert radiologist at the central imaging center using a semiquantitative grading scale: Grade 1, 20% to 25% reduction in vertebral height (anterior, middle, or posterior); Grade 2, 25% to 40% reduction in height; Grade 3, greater than 40% reduction in height. A new vertebral fracture was defined as a fracture in a previously undeformed vertebrae including new compression fractures, defined as those compression fractures having a decrease in total anterior or posterior height of at least 25% from baseline. New vertebral fractures includes morphometric vertebral fractures identified from on study x-rays and clinical vertebral fractures confirmed by x-rays.
| Participants | Placebo | Denosumab |
|---|---|---|
| Number of Participants With New Vertebral Fractures | 49 | 27 |
Assessment of vertebral fractures was performed by an expert radiologist at the central imaging center using a semiquantitative grading scale: Grade 1, 20% to 25% reduction in vertebral height (anterior, middle, or posterior); Grade 2, 25% to 40% reduction in height; Grade 3, greater than 40% reduction in height. A new vertebral fracture was defined as a fracture in a previously undeformed vertebrae including new compression fractures, defined as those compression fractures having a decrease in total anterior or posterior height of at least 25% from baseline. New vertebral fractures includes morphometric vertebral fractures identified from on study x-rays and clinical vertebral fractures confirmed by x-rays. Worsening of pre-existing fractures was defined as an increase in fracture severity of at least 1 grade on the semiquantitative scale.
| Participants | Placebo | Denosumab |
|---|---|---|
| Number of Participants With New or Worsening Vertebral Fractures | 55 | 31 |
DFS was defined as the time interval from the randomization date to the date of first evidence of local or distant metastases, contra-lateral breast cancer, secondary carcinoma, or death from any cause (whichever occurred first). Participants last known to be alive, who did not experience recurrence of disease, were censored at their last contact date or at the data cut-off date whichever came first.
| Days | Placebo | Denosumab |
|---|---|---|
| Disease-free Survival (DFS) | NA (NA to NA) | NA (NA to NA) |
BMFS was defined as the time interval from randomization to first occurrence of bone metastasis or death from any cause, whichever comes first. Participants last known to be alive, who did not experience bone metastasis, were censored at their last assessment (i.e., bone scan) date or at the last contact date, whichever comes first.
| Days | Placebo | Denosumab |
|---|---|---|
| Bone Metastases-free Survival (BMFS) | NA (NA to NA) | NA (NA to NA) |
OS was defined as the time from randomization to death from any cause.
| Days | Placebo | Denosumab |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
Collected over Double-blind (DB) phase: from 1st dose of study drug to 30 days after last dose; Open-label (OL) phase: from 1st dose of OL study drug to 30 days after last dose. Median duration of treatment in DB phase: Placebo 35.4 months and denosumab 35.5 months. Median duration of treatment in OL phase: 37 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind Phase: Placebo | — | 515/1,690 (30.5%) | 838/1,690 (49.6%) |
| Double-blind Phase: Denosumab | — | 521/1,709 (30.5%) | 882/1,709 (51.6%) |
| Open-label Phase: Placebo/Denosumab | — | 40/245 (16.3%) | 0/245 (0%) |
| Open-label Phase: Denosumab/Denosumab | — | 0/1 (0%) | 0/1 (0%) |
| Event | Double-blind Phase: Placebo | Double-blind Phase: Denosumab | Open-label Phase: Placebo/Denosumab | Open-label Phase: Denosumab/Denosumab |
|---|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 59/1690 | 62/1709 | 2/245 | 0/1 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 15/1690 | 14/1709 | 5/245 | 0/1 |
| CataractEye disorders | 28/1690 | 16/1709 | 2/245 | 0/1 |
| Meniscus injuryInjury, poisoning and procedural complications | 24/1690 | 23/1709 | 0/245 | 0/1 |
| GoitreEndocrine disorders | 12/1690 | 21/1709 | 1/245 | 0/1 |
| Atrial fibrillationCardiac disorders | 11/1690 | 14/1709 | 3/245 | 0/1 |
| DiverticulitisInfections and infestations | 9/1690 | 9/1709 | 3/245 | 0/1 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/1690 | 1/1709 | 3/245 | 0/1 |
| ErysipelasInfections and infestations | 10/1690 | 15/1709 | 1/245 | 0/1 |
| Hypertensive crisisVascular disorders | 14/1690 | 10/1709 | 1/245 | 0/1 |
| Event | Double-blind Phase: Placebo | Double-blind Phase: Denosumab | Open-label Phase: Placebo/Denosumab | Open-label Phase: Denosumab/Denosumab |
|---|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 446/1690 | 441/1709 | 0/245 | 0/1 |
| Hot flushVascular disorders | 234/1690 | 270/1709 | 0/245 | 0/1 |
| Back painMusculoskeletal and connective tissue disorders | 146/1690 | 151/1709 | 0/245 | 0/1 |
| Bone painMusculoskeletal and connective tissue disorders | 111/1690 | 139/1709 | 0/245 | 0/1 |
| HypertensionVascular disorders | 94/1690 | 111/1709 | 0/245 | 0/1 |
| FatigueGeneral disorders | 100/1690 | 109/1709 | 0/245 | 0/1 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 85/1690 | 107/1709 | 0/245 | 0/1 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 61/1690 | 89/1709 | 0/245 | 0/1 |
| Spinal painMusculoskeletal and connective tissue disorders | 73/1690 | 89/1709 | 0/245 | 0/1 |
| Scar painSkin and subcutaneous tissue disorders | 86/1690 | 78/1709 | 0/245 | 0/1 |
| Age, Continuous(years) | Placebo | Denosumab | Total |
|---|---|---|---|
| Mean | 64.6 ± 8.0 | 64.0 ± 7.9 | 64.3 ± 8.0 |
| Sex: Female, Male(Participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| Female | 1709 | 1711 | 3420 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| White/Caucasian | 1700 | 1702 | 3402 |
| Asian | 7 | 5 | 12 |
| Hispanic/Latino | 1 | 3 | 4 |
| Black/Afro-Caribbean | 0 | 1 | 1 |
| Missing | 1 | 0 | 1 |
| Stratification Factor: Type of Hospital(participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| Major Academic Center | 632 | 633 | 1265 |
| Other Center | 1077 | 1078 | 2155 |
| Stratification Factor: Prior Aromatase inhibitor Use(Participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| No | 269 | 270 | 539 |
| Yes | 1440 | 1441 | 2881 |
| Stratification Factor: Total Lumbar Spine BMD T-score(Participants) | Placebo | Denosumab | Total |
|---|---|---|---|
| T-score < -1.0 | 775 | 773 | 1548 |
| T-score ≥ -1.0 | 934 | 938 | 1872 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Ran from Dec 2006 to primary completion in Oct 2014, 93 months.
Results were first posted in Nov 2015, 1 year after primary completion. A results delay was requested in Sep 2015.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 93 months is above that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Denosumab · Zoledronic Acid